Close

Connect Biopharma Completes Enrollment of CBP-201 Global Phase 2 Clinical Trial in Moderate-to-Severe Atopic Dermatitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/24/2024

1. TSLA
2. SPY
3. GM
4. SPOT
5. AMZN
6. SHW
7. AAPL
8. IBM
9. MINN
10. NVDA


Go back to Connect Biopharma Completes Enrollment of CBP-201 Global Phase 2 Clinical Trial in Moderate-to-Severe Atopic Dermatitis
(NASDAQ: CNTB) Delayed: 1.39 +0.04 (2.96%)
Previous Close $1.35    52 Week High $ 
Open $1.34    52 Week Low $ 
Day High $1.46    P/E N/A 
Day Low $1.32    EPS $ 
Volume 73,419